Our article in Nature’s Biopharma Dealmakers ‘Industry shows trust in cell and gene therapy platform technologies’
We were asked to share our insights on cell and gene therapy deals and financing in the renowned scientific publication Biopharma Dealmakers by Nature. The take-away: these companies continued to attract large deals in 2022 despite the financing landscape looking gloomier than ever.
Read full post >
November 24, 2022
Biotech valuation courses
Our valuation courses aim to guide you through the basic mechanics of biotech valuation and provide benchmark data and references that may serve as assumptions about key factors. Our goal has been to create something actionable for CEOs, business developers, board members and investors in small biotech companies to use when preparing negotiations for financing rounds or business deals.
Read more >
We understand the business issues facing smaller biotech companies and share a passion with our clients to drive the future of medicine.
We support leaders with actionable recommendations and insights with a fervor and razor-sharp focus. Our approach is doing so by creating tailored solutions to challenging business issues and crafting strategies to achieve business goals and brand visibility. Whether it is business development, asset valuation or communication, we are a reliable partner that always walk that extra mile.